| 1 |
33471836 | PI3k inhibitors (BKM120 and BYL719) as radiosensitizers for head and neck squamous cell carcinoma during radiotherapy. | 2021 |
1 |
| 2 |
32005746 | A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors. | 2020 Jun 1 |
1 |
| 3 |
32898555 | Buparlisib modulates PD-L1 expression in head and neck squamous cell carcinoma cell lines. | 2020 Nov 1 |
1 |
| 4 |
30982255 | [NVP-BKM120 in combination with letrozole inhibit human breast cancer stem cells via PI3K/mTOR pathway]. | 2019 Apr 9 |
1 |
| 5 |
27507562 | Combination of phosphotidylinositol-3-kinase targeting with cetuximab and irradiation: A preclinical study on an orthotopic xenograft model of head and neck cancer. | 2017 Jan |
2 |
| 6 |
27986714 | Benefit Mixed with Caution for Buparlisib. | 2017 Feb |
1 |
| 7 |
28662162 | BKM120 induces apoptosis and inhibits tumor growth in medulloblastoma. | 2017 |
1 |
| 8 |
27531477 | [Molecular mechanisms of resistance to phosphatidyl inositol 3-kinase inhibitors in triple-negative breast cancer cells]. | 2016 Aug |
2 |
| 9 |
26402468 | Evaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric Bone and Soft Tissue Sarcomas. | 2015 |
1 |
| 10 |
22159814 | NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations. | 2012 Apr |
1 |